• The technology described in this briefing is the NephroCheck (including VITROS NephroCheck) test. It is an in vitro diagnostic test used to measure urinary biomarkers of kidney injury as an aid in detecting acute kidney injury.

  • The innovative aspects are that NephroCheck is claimed to predict the risk of kidney injury earlier than current clinical assessment and testing methods.

  • The intended place in therapy would be in addition to standard care. It would be most likely to be used in critically ill patients.

  • The main points from the evidence summarised in this briefing are from 3 validation and diagnostic accuracy studies (n=1,262) and 2 randomised controlled trials (n=397). The evidence suggests that an increase in urinary TIMP2 and IGFBP7 in the critically ill may be a predictor of acute kidney injury risk.

  • Key uncertainty is that there are no studies comparing NephroCheck-guided implementation of preventive care with standard NHS practice.

  • The cost of a NephroCheck test cartridge is ¬£49.80 (excluding VAT; not including the cost of the platform for the test). This would represent an additional cost compared with standard clinical assessment. This might be offset if early recognition of acute kidney injury were to result in less resource-intensive preventive care and so reduce the costs of managing acute kidney injury.